Steven Cohen's TSHA Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 461,856 shares of Taysha Gene Therapies, Inc. (TSHA) worth $2.06 M, representing 0.00% of the portfolio. First purchased in 2020-Q3, this medium-term investment has been held for 12 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in TSHA, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 4.57 M shares. Largest reduction occurred in Q4 2025, reducing 3.46 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Taysha Gene Therapies (TSHA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Taysha Gene Therapies (TSHA) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -3.41 M | Reduce 88.06% | 461,856 | $4.47 |
| Q4 2025 | -3.46 M | Reduce 47.23% | 3.87 M | $5.50 |
| Q3 2025 | +13,856 | Add 0.19% | 7.33 M | $3.27 |
| Q2 2025 | +2.75 M | Add 60.13% | 7.32 M | $2.31 |
| Q1 2025 | +4.57 M | New Buy | 4.57 M | $1.39 |
| Q2 2024 | -1.11 M | Sold Out | 0 | $0.00 |
| Q1 2024 | -1.57 M | Reduce 58.59% | 1.11 M | $2.87 |
| Q4 2023 | +1.75 M | Add 187.01% | 2.69 M | $1.77 |
| Q3 2023 | +936,550 | New Buy | 936,550 | $3.16 |
| Q1 2021 | -13,366 | Sold Out | 0 | $0.00 |
| Q4 2020 | -186,634 | Reduce 93.32% | 13,366 | $26.56 |
| Q3 2020 | +200,000 | New Buy | 200,000 | $22.40 |
Steven Cohen's Taysha Gene Therapies Investment FAQs
Steven Cohen first purchased Taysha Gene Therapies, Inc. (TSHA) in Q3 2020, acquiring 200,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Taysha Gene Therapies, Inc. (TSHA) for 12 quarters since Q3 2020.
Steven Cohen's largest addition to Taysha Gene Therapies, Inc. (TSHA) was in Q1 2025, adding 4,569,678 shares worth $6.35 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 461,856 shares of Taysha Gene Therapies, Inc. (TSHA), valued at approximately $2.06 M.
As of the Q1 2026 filing, Taysha Gene Therapies, Inc. (TSHA) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Taysha Gene Therapies, Inc. (TSHA) was 7,331,470 shares, as reported at the end of Q3 2025.